Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 11/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | MST1R | Q04912 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338944 | 0.75 | LTK (0.33) | SCN5ANOTUMRETMETLTK | |
| SCHEMBL20772490 | 0.73 | SCN5A (0.51) | SCN5ANOTUMPDE5ARETMET | |
| SCHEMBL3793191 | 0.71 | SCN5A (0.43) | SCN5ANOTUMPDE5ARETMET | |
| SCHEMBL406976 | 0.69 | SCN5A (0.48) | SCN5ANOTUM | |
| SCHEMBL17403215 | 0.69 | TDP1 (0.47) | SCN5ANOTUM | |
| SCHEMBL6730706 | 0.69 | SCN5A (0.44) | SCN5ANOTUMPDE5A | |
| SCHEMBL16154734 | 0.69 | SCN5A (0.48) | SCN5ANOTUM | |
| SCHEMBL20773134 | 0.69 | SCN5A (0.48) | SCN5ANOTUMPDE5ARETMET | |
| SCHEMBL18632542 | 0.68 | SCN5A (0.61) | SCN5ANOTUM | |
| SCHEMBL10203097 | 0.68 | SCN5A (0.61) | SCN5ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017046350-A1 | TRIAZOLONES DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081324-A1 | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081324-A1 | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081324-A1 | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease | MAPT, TPMT, TTR | SCN5A 1331/4885NOTUM 1088/4885PDE5A 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.